摘要
目的优化丹参二萜醌(diterpenoid tanshinone,DT)羟丙基-β-环糊精(hydroxypropyl-β-cyclodextrin,HP-β-CD)包合物(inclusion complex,IC)(DT&HP-β-CD@IC)制备工艺。方法在单因素试验的基础上,选择DT与HP-β-CD的配比、包合温度、包合时间为考察因素,以DT包封率及包合物载药量为综合评价指标,利用Box-Behnken响应面优化DT&HP-β-CD@IC制备工艺,并采用红外光谱法、紫外光谱法、薄层色谱法及扫描电子显微镜法对DT&HP-β-CD@IC进行评价。结果DT&HP-β-CD@IC最佳制备工艺为HP-β-CD质量浓度0.1 g/mL,药物与载体材料配比1∶3,包合时间2 h,包合温度40℃。DT&HP-β-CD@IC的包封率达68.78%,载药量达5.44%。紫外、红外光谱和薄层色谱等结果表明DT&HP-β-CD@IC的形成。结论DT&HP-β-CD@IC载药量较高,溶解性有一定的提高。
Objective To optimize the preparation process of diterpenoid tanshinone(DT)hydroxypropyl-β-cyclodextrin(HP-β-CD)inclusion complex(IC)(DT&HP-β-CD@IC).Methods Based on the single factor test,the ratio of DT and HP-β-CD,the inclusion temperature,and the inclusion time were selected as the investigating factors,the encapsulation efficiency and drug-loading of the inclusion complex were used as the evaluation index.The Box-Behnken response surface was used to optimize the preparation process of the DT&HP-β-CD@IC,and the inclusion complex was evaluated by infrared spectroscopy,ultraviolet spectroscopy,thin layer chromatography and scanning electron microscopy.Results The optimal preparation process of the inclusion complex was as follows:HP-β-CD concentration was 0.1 g/mL,the ratio of drug to carrier material was 1:3,the inclusion time was 2 h,and the inclusion temperature was 40℃.The encapsulation rate of DT&HP-β-CD@IC was 68.78%,and the drug loading was 5.44%.The results of ultraviolet,infrared spectroscopy and thin-layer chromatography indicated the formation of inclusion complex.Conclusion DT&HPβ-CD@IC has a high encapsulation efficiency and a certain improvement in solubility.
作者
苏行
刘慧芳
刘泽莹
楼招欢
张光霁
SU Hang;LIU Hui-fang;LIU Ze-ying;LOU Zhao-huan;ZHANG Guang-ji(Key Labortary of Blood-Stasis-Toxin Syndrome of Zhejiang Province,School of Basic Medical Sciences,Zhejiang Chinese Medical University,Hangzhou 310053,China;School of Pharmaceutical Sciences,Zhejiang Chinese Medical University,Hangzhou 310053,China)
出处
《中草药》
CAS
CSCD
北大核心
2023年第10期3132-3140,共9页
Chinese Traditional and Herbal Drugs
基金
浙江省科技计划项目省级重点研发计划(2019C03072)
浙江省中医药科技计划项目(2023ZR081)。